Compare Quest Diagnostics Inc (DGX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tenet Healthcare Corporation — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Tenet Healthcare Corporation trades at $263.45 (market cap $20.98B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Tenet Healthcare Corporation for 15 Days on average.
| DGX | THC | |
|---|---|---|
Market Cap | $25.48B | $20.98B |
Volume | 941,866 | 428,008 |
Sector | Health | Health |
52-Week High | $247.45 | $280.77 |
52-Week Low | $173.49 | $161.37 |
Typical Hold Time | 56 Days | 15 Days |
Enterprise Value | $31.23B | $32.06B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
